CIK 0001662774
- Non-accelerated filer
- Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 901024039
- Phone
- +1 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-03 | Dominy Stephen S. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +125,000 | 125,000 | ||
| 2021-11-12 | Dominy Stephen S. Chief Scientific Officer | Purchase | +763 | $14.40 | $11K | 1,217,086 |
| 2020-12-11 | Dominy Stephen S. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2020-12-11 | Dominy Stephen S. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2020-02-06 | Dominy Stephen S. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 |
Page 1 of 1 · 5 trades